4.56
前日終値:
$4.54
開ける:
$4.62
24時間の取引高:
26,025
Relative Volume:
0.34
時価総額:
$17.98M
収益:
-
当期純損益:
$-117.67M
株価収益率:
-1.4757
EPS:
-3.09
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
+7.04%
6か月 パフォーマンス:
+1,598%
1年 パフォーマンス:
+591.85%
Athira Pharma Inc Stock (ATHA) Company Profile
名前
Athira Pharma Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ATHA
Athira Pharma Inc
|
4.56 | 17.91M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.06 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.11 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.15 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.65 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.22 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Athira Pharma Inc (ATHA) 最新ニュース
Why Athira Pharma Inc. stock could benefit from AI revolutionJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Athira Pharma Inc. stock performs during Fed tightening cycles2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Athira Pharma Inc. stock outlook for YEARGap Up & Weekly Market Pulse Updates - newser.com
Why Athira Pharma Inc. stock is popular among millennialsEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
How to escape a deep drawdown in Athira Pharma Inc.Earnings Growth Summary & Consistent Return Strategy Ideas - newser.com
What makes Athira Pharma Inc. stock attractive to growth fundsJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Will Athira Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Top chart patterns to watch in Athira Pharma Inc.July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC) - The Globe and Mail
What indicators show strength in Athira Pharma Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - newser.com
What analyst consensus says on Athira Pharma Inc. stock2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Will Athira Pharma Inc. continue its uptrendEarnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
Update Recap: Is Athira Pharma Inc. stock ready for breakoutBull Run & Daily Chart Pattern Signal Reports - Fundação Cultural do Pará
Risk vs reward if holding onto Athira Pharma Inc.Quarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Athira Pharma Inc. stock volume spike explainedWeekly Profit Report & Weekly Consistent Profit Watchlists - newser.com
Can Athira Pharma Inc. stock deliver consistent earnings growthDollar Strength & Long-Term Growth Portfolio Plans - newser.com
Real time alert setup for Athira Pharma Inc. performanceRate Cut & Consistent Return Strategy Ideas - newser.com
Is Athira Pharma Inc. stock cheap at current valuationJuly 2025 Review & Weekly Stock Performance Updates - newser.com
Athira Pharma Cuts Losses And Sets Sights On ALS Trials - Finimize
Athira Pharma, Inc. (ATHA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Athira Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Athira Pharma Inc (ATHA) 財務データ
収益
当期純利益
現金流量
EPS
Athira Pharma Inc (ATHA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
大文字化:
|
ボリューム (24 時間):